Media stories about Eleven Biotherapeutics (NASDAQ:EBIO) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Eleven Biotherapeutics earned a news sentiment score of 0.22 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.917816483704 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Separately, ValuEngine upgraded shares of Eleven Biotherapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.
Shares of Eleven Biotherapeutics (NASDAQ:EBIO) traded up $0.03 during mid-day trading on Friday, reaching $0.93. 434,171 shares of the company’s stock were exchanged, compared to its average volume of 1,137,811. The company has a market cap of $29.45, a price-to-earnings ratio of -0.86 and a beta of 3.19. Eleven Biotherapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $2.54.
Eleven Biotherapeutics (NASDAQ:EBIO) last announced its quarterly earnings results on Monday, November 20th. The biopharmaceutical company reported ($0.37) EPS for the quarter.
ILLEGAL ACTIVITY NOTICE: “Eleven Biotherapeutics (EBIO) Getting Somewhat Favorable Press Coverage, Study Finds” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/18/eleven-biotherapeutics-ebio-getting-somewhat-favorable-press-coverage-study-finds.html.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.
Receive News & Ratings for Eleven Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.